Analyst targets post earnings | IMGN Message Board Posts


ImmunoGen, Inc.

  IMGN website

IMGN   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  52175 of 52340  at  5/14/2021 12:28:44 PM  by

Biotechbeagle

The following message was updated on 5/14/2021 12:29:56 PM.

Analyst targets post earnings

  
Piper says ImmunoGen's 'modest' timeline slip makes cash runway 'more tenuous' After ImmunoGen reported Q1 results and said that timelines around mirvetuximab's pivotal and confirmatory studies in platinum-resistant ovarian cancer have been pushed slightly out due to a COVID-related enrollment slowdown, Piper Sandler analyst Joseph Catanzaro said the "modest slip" in timelines makes the company's current cash runway "perhaps a bit more tenuous." While he said he continues to "take a glass half full" view, Catanzaro keeps a Neutral rating and $6.50 price target on ImmunoGen shares.
 
Leerink Partners analyst Jonathan Chang maintained a Hold rating on Immunogen on Monday, setting a price target of $6 
 
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Immunogen on Tuesday, setting a price target of $12
 
Canaccord Genuity maintained a Buy rating on ImmunoGen, with a price target of $12.00
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
52176 Re: Analyst targets post earnings pierre piav 0 5/14/2021 3:09:23 PM


Financial Market Data provided by
.
Loading...